Newswise — The Board of Directors of the American Association for Cancer Research recently elected Beverly W. Aisenbrey and Tyler Jacks, Ph.D., as trustees of the AACR Foundation for the Prevention and Cure of Cancer (AACR Foundation). Elected at the 2008 AACR Annual Meeting, each will serve a term of three years and may be re-elected. As a result of his status as AACR's president-elect, Jacks joins the Foundation board as an ex officio member whose term coincides with his AACR leadership term.
Beverly W. Aisenbrey is a managing director in the New York office of Frederic W. Cook & Co., Inc. She has been with the firm since 1982, held the office of treasurer and continues to serve on its board of directors. An independent advisor to dozens of leading companies, Aisenbrey designs performance-based compensation programs and consults on change-in-control, severance and employment agreements. In this role, she most often works directly with the board of directors' compensation committee.
Aisenbrey is a trustee of Rutgers University, and a member of several advisory boards, including Rutgers Business School and the New Jersey Chapter of the National Association of Corporate Directors and Compensation and Benefits Review. She belongs to the Founding Circle of the Rutgers Women's Business Leadership Initiative. Aisenbrey received her B.A. from Douglass College and her M.B.A. in finance from Rutgers University.
Tyler E. Jacks, Ph.D., is the director of the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, the David H. Koch professor of biology at MIT, and an investigator with the Howard Hughes Medical Institute.
Jacks' research interests are in the genetic events that contribute to the development of cancer. His laboratory has engineered a series of novel, mutant mouse strains that accurately mimic human cancer and thus serve as animal models for exploring the cellular pathways regulated by cancer-associated genes.
Jacks is a long-standing member of the AACR, and has served in several leadership positions for the AACR, including as a board member from 2001-2004, as a member of the nominating committee from 2004-2006 and as a member of the Annual Meeting 2003 program committee. Jacks was previously senior editor of Molecular Cancer Research. Jacks received his B.S. in biology from Harvard University and his Ph.D. in biochemistry from the University of California, San Francisco. He completed his post-doctoral training at the Whitehead Institute for Biomedical Research, MIT.
AACR Foundation trustees work collectively to fulfill the Foundation's mission to accelerate progress in the conquest of cancer by providing financial support for scientific research, education and communication. The Foundation funds programs deemed by the American Association for Cancer Research to be of the highest priority and impact.
For more information about the AACR Foundation for the Prevention and Cure of Cancer and to learn how you can help, please visit our website.
Editor's note: High resolution photos of Aisenbrey and Jacks are available upon request.
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and 80 other countries. AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. AACR publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. Its most recent publication and its sixth major journal, Cancer Prevention Research, is dedicated exclusively to cancer prevention, from preclinical research to clinical trials. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
RSS